Status:
ACTIVE_NOT_RECRUITING
Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout
Lead Sponsor:
Attune Health Research, Inc.
Collaborating Sponsors:
Horizon Pharma Ireland, Ltd., Dublin Ireland
Conditions:
Gout
Eligibility:
All Genders
18+ years
Brief Summary
Gout is an autoinflammatory disease characterized by flares of painful joint inflammation. This inflammation occurs in response to uric acid that crystallizes. After a gout attack, patients usually en...
Eligibility Criteria
Inclusion
- Adult patients with gout diagnosed by a Rheumatologist.
- patients with a history of at least two gout attacks in the target joint
- Patients with a target joint amenable to biopsy. Target joint defined as:
- Joint that has been affected by acute gout attack at least twice in the 12 months prior to enrollment.
- Ultrasound finds grade 2 gray-scale synovitis in joint. Joint is amenable to biopsy. At the time of enrollment, the joint is without signs of acute inflammation: redness, swelling, and severe pain (\>7/10).
Exclusion
- Patients on anti-coagulation therapy.
- Patients with an active infection.
- Tophus present at the biopsy site.
- Target joint with signs of acute gout attack (pain \>7/10, redness, warmth)
- Known chondrocalcinosis
Key Trial Info
Start Date :
January 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 3 2024
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04125459
Start Date
January 22 2020
End Date
October 3 2024
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Attune Health Research Inc.
Beverly Hills, California, United States, 90211